Simona Balestrini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/305762/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The <scp>ENIGMAâ€Epilepsy</scp> working group: Mapping disease from large data sets. Human Brain Mapping, 2022, 43, 113-128.	3.6	47
2	Expanding the genetic and phenotypic spectrum of <scp><i>CHD2</i></scp> â€related disease: From early neurodevelopmental disorders to adultâ€onset epilepsy. American Journal of Medical Genetics, Part A, 2022, 188, 522-533.	1.2	13
3	Non‧tationary Outcome of Alternating Hemiplegia of Childhood into Adulthood. Movement Disorders Clinical Practice, 2022, 9, 206-211.	1.5	1
4	Electroclinical Features and Long-term Seizure Outcome in Patients With Eyelid Myoclonia With Absences. Neurology, 2022, 98, .	1.1	15
5	Methodology for classification and definition of epilepsy syndromes with list of syndromes: Report of the ILAE Task Force on Nosology and Definitions. Epilepsia, 2022, 63, 1333-1348.	5.1	84
6	Efficacy and Safety of Long-Term Treatment with Stiripentol in Children and Adults with Drug-Resistant Epilepsies: A Retrospective Cohort Study of 196 Patients. Drugs - Real World Outcomes, 2022, 9, 451-461.	1.6	6
7	Complex epilepsy: it's all in the history. Practical Neurology, 2021, 21, 153-156.	1.1	3
8	Clinical outcomes of COVID-19 in long-term care facilities for people with epilepsy. Epilepsy and Behavior, 2021, 115, 107602.	1.7	11
9	The aetiologies of epilepsy. Epileptic Disorders, 2021, 23, 1-16.	1.3	35
10	The impact of COVIDâ€19 in Dravet syndrome: A UK survey. Acta Neurologica Scandinavica, 2021, 143, 389-395.	2.1	7
11	Climate change and epilepsy: Insights from clinical and basic science studies. Epilepsy and Behavior, 2021, 116, 107791.	1.7	30
12	Increased facial asymmetry in focal epilepsies associated with unilateral lesions. Brain Communications, 2021, 3, fcab068.	3.3	5
13	Real-life survey of pitfalls and successes of precision medicine in genetic epilepsies. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1044-1052.	1.9	30
14	Sub-genic intolerance, ClinVar, and the epilepsies: A whole-exome sequencing study of 29,165 individuals. American Journal of Human Genetics, 2021, 108, 965-982.	6.2	35
15	Intracerebral electrical stimulations of the temporal lobe: A stereoelectroencephalography study. European Journal of Neuroscience, 2021, 54, 5368-5383.	2.6	10
16	K.Vita: a feasibility study of a blend of medium chain triglycerides to manage drug-resistant epilepsy. Brain Communications, 2021, 3, fcab160.	3.3	17
17	Late diagnoses of Dravet syndrome: How many individuals are we missing?. Epilepsia Open, 2021, 6, 770-776.	2.4	9
18	Postictal Psychosis in Epilepsy: A Clinicogenetic Study. Annals of Neurology, 2021, 90, 464-476.	5.3	11

SIMONA BALESTRINI

#	Article	IF	CITATIONS
19	Monogenic Epilepsies. Neurology, 2021, 97, 817-831.	1.1	38
20	Two-center experience of cannabidiol use in adults with Dravet syndrome. Seizure: the Journal of the British Epilepsy Association, 2021, 91, 5-8.	2.0	11
21	The impact of SARS-CoV-2 vaccination in Dravet syndrome: A UK survey. Epilepsy and Behavior, 2021, 124, 108258.	1.7	15
22	Rare and Complex Epilepsies from Childhood to Adulthood: Requirements for Separate Management or Scope for a Lifespan Holistic Approach?. Current Neurology and Neuroscience Reports, 2021, 21, 65.	4.2	4
23	Transcranial magnetic stimulation as a tool to understand genetic conditions associated with epilepsy. Epilepsia, 2020, 61, 1818-1839.	5.1	9
24	Cardiac phenotype in <i>ATP1A3</i> -related syndromes. Neurology, 2020, 95, e2866-e2879.	1.1	19
25	Ammonia: what adult neurologists need to know. Practical Neurology, 2020, , practneurol-2020-002654.	1.1	2
26	Epilepsy subtype-specific copy number burden observed in a genome-wide study of 17 458 subjects. Brain, 2020, 143, 2106-2118.	7.6	47
27	Muscle and brain sodium channelopathies: genetic causes, clinical phenotypes, and management approaches. The Lancet Child and Adolescent Health, 2020, 4, 536-547.	5.6	13
28	Perampanel Confirms to Be Effective and Well-Tolerated as an Add-On Treatment in Patients With Brain Tumor-Related Epilepsy (PERADET Study). Frontiers in Neurology, 2020, 11, 592.	2.4	32
29	Transcranial magnetic stimulation as a biomarker of treatment response in children with epilepsy. Developmental Medicine and Child Neurology, 2020, 62, 770-770.	2.1	1
30	Cortical myoclonus and epilepsy in a family with a new SLC20A2 mutation. Journal of Neurology, 2020, 267, 2221-2227.	3.6	5
31	The landscape of epilepsy-related GATOR1 variants. Genetics in Medicine, 2019, 21, 398-408.	2.4	137
32	Ultra-Rare Genetic Variation in the Epilepsies: A Whole-Exome Sequencing Study of 17,606 Individuals. American Journal of Human Genetics, 2019, 105, 267-282.	6.2	237
33	Comparative effectiveness of antiepileptic drugs in juvenile myoclonic epilepsy. Epilepsia Open, 2019, 4, 420-430.	2.4	34
34	Intronic ATTTC repeat expansions in STARD7 in familial adult myoclonic epilepsy linked to chromosome 2. Nature Communications, 2019, 10, 4920.	12.8	99
35	Cerebellar, limbic, and midbrain volume alterations in sudden unexpected death in epilepsy. Epilepsia, 2019, 60, 718-729.	5.1	54
36	Clinical spectrum of <i>STX1B</i> -related epileptic disorders. Neurology, 2019, 92, e1238-e1249.	1.1	43

SIMONA BALESTRINI

#	Article	IF	CITATIONS
37	Drug-resistant epilepsy, early-onset hypertension and white matter lesions: a hidden paraganglioma. BMJ Case Reports, 2019, 12, e228348.	0.5	0
38	Pharmacogenomics in epilepsy. Neuroscience Letters, 2018, 667, 27-39.	2.1	109
39	Ring Chromosome 17 Not Involving the Miller-Dieker Region: A Case with Drug-Resistant Epilepsy. Molecular Syndromology, 2018, 9, 38-44.	0.8	7
40	Neurologic phenotypes associated with <i>COL4A1</i> / <i>2</i> mutations. Neurology, 2018, 91, e2078-e2088.	1.1	97
41	Personalized treatment in the epilepsies: challenges and opportunities. Expert Review of Precision Medicine and Drug Development, 2018, 3, 237-247.	0.7	3
42	Genomeâ€wide association study: Exploring the genetic basis for responsiveness to ketogenic dietary therapies for drugâ€resistant epilepsy. Epilepsia, 2018, 59, 1557-1566.	5.1	23
43	10.2174/1381612823666170809115827. Current Pharmaceutical Design, 2018, 23, 5667-5690.	1.9	9
44	Diagnostic Biomarkers of Epilepsy. Current Pharmaceutical Biotechnology, 2018, 19, 440-450.	1.6	20
45	Audit of use of stiripentol in adults with Dravet syndrome. Acta Neurologica Scandinavica, 2017, 135, 73-79.	2.1	36
46	Clinical spectrum and genotype–phenotype associations of KCNA2-related encephalopathies. Brain, 2017, 140, 2337-2354.	7.6	117
47	From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We?. Current Pharmaceutical Design, 2017, 22, 6426-6433.	1.9	8
48	De novo mutations of <i>KIAA2022</i> in females cause intellectual disability and intractable epilepsy. Journal of Medical Genetics, 2016, 53, 850-858.	3.2	47
49	<i>TBC1D24</i> genotype–phenotype correlation. Neurology, 2016, 87, 77-85.	1.1	97
50	Retinal nerve fibre layer thinning is associated with drug resistance in epilepsy. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 396-401.	1.9	18
51	The challenges of treating epilepsy with 25 antiepileptic drugs. Pharmacological Research, 2016, 107, 211-219.	7.1	72
52	Safe use of perampanel in a carrier of variegate porphyria. Practical Neurology, 2016, 16, 217-219.	1.1	3
53	Psychiatric comorbidities in patients from seven families with autosomal dominant cortical tremor, myoclonus, and epilepsy. Epilepsy and Behavior, 2016, 56, 38-43.	1.7	21
54	Reply: The dorsal cingulate cortex as a critical gateway in the network supporting conscious awareness. Brain, 2016, 139, e24-e24.	7.6	2

SIMONA BALESTRINI

#	Article	IF	CITATIONS
55	Diagnostic delay and prognosis in primary central nervous system lymphoma compared with glioblastoma multiforme. Neurological Sciences, 2016, 37, 23-29.	1.9	20
56	Genome-wide Polygenic Burden of Rare Deleterious Variants in Sudden Unexpected Death in Epilepsy. EBioMedicine, 2015, 2, 1063-1070.	6.1	74
57	Applying a perceptions and practicalities approach to understanding nonadherence to antiepileptic drugs. Epilepsia, 2015, 56, 1398-1407.	5.1	38
58	Markers for the Risk of Progression from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 45, 883-890.	2.6	44
59	Sex-Associated Differences in the Modulation of Vascular Risk in Patients with Asymptomatic Carotid Stenosis. Journal of Cerebral Blood Flow and Metabolism, 2015, 35, 684-688.	4.3	13
60	Multimodal responses induced by cortical stimulation of the parietal lobe: a stereo-electroencephalography study. Brain, 2015, 138, 2596-2607.	7.6	64
61	Structural imaging biomarkers of sudden unexpected death in epilepsy. Brain, 2015, 138, 2907-2919.	7.6	95
62	Increased Common Carotid Artery Wall Thickness Is Associated with Rapid Progression of Asymptomatic Carotid Stenosis. Journal of Neuroimaging, 2014, 24, 473-478.	2.0	11
63	Generalized epilepsy in a patient with myotonic dystrophy type 2. Neurological Sciences, 2014, 35, 489-490.	1.9	3
64	Coasting, embryo development and outcomes of blastocyst transfer: a case–control study. Reproductive BioMedicine Online, 2014, 29, 231-238.	2.4	7
65	Percutaneous transluminal angioplasty for chronic cerebrospinal venous insufficiency in multiple sclerosis: dichotomy between subjective and objective outcome scores. Neurological Sciences, 2013, 34, 2205-2210.	1.9	8
66	Emergency room access for recurring seizures: when and why. European Journal of Neurology, 2013, 20, 1411-1416.	3.3	9
67	One-Year Progression of Moderate Asymptomatic Carotid Stenosis Predicts the Risk of Vascular Events. Stroke, 2013, 44, 792-794.	2.0	36
68	Severe carotid stenosis and impaired cerebral hemodynamics can influence cognitive deterioration. Neurology, 2013, 80, 2145-2150.	1.1	103
69	Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization. Neurology, 2013, 80, 2170-2170.	1.1	0